Core Points - Zhejiang Huahai Pharmaceutical Co., Ltd. has received the drug registration certificate for Nimodipine Tablets from the National Medical Products Administration, indicating compliance with drug registration requirements [1][4] - Nimodipine Tablets are indicated for improving low motivation due to sequelae of cerebral infarction and are particularly effective in early treatment of vascular dementia [2] - The company has invested approximately RMB 8.99 million in the research and development of Nimodipine Tablets [3] Drug Information - Drug Name: Nimodipine Tablets - Dosage Forms: Tablets - Specifications: 5mg, 10mg - Registration Category: Class 3 Chemical Drug - Approval Numbers: National Drug Approval Code H20254671, H20254672 [1][2] Market Impact - The approval of Nimodipine Tablets enhances the company's product line and market competitiveness, contributing positively to its business development [4] - The domestic market sales for Nimodipine Tablets are projected to be approximately RMB 555 million in 2024 [2]

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-077 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 注册分类：化学药品 3 类 申请人：浙江华海药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的尼麦角林片的《药品注册证书》，现将 相关情况公告如下： 一、药品的基本情况 药品名称：尼麦角林片 剂型：片剂 规格：5mg、10mg 申请事项：药品注册（境内生产） 四、风险提示 公司高度重视药品研发，严格控制药品研发、生产、销售环节的质量和安全。 但产品的生产和销售容易受国家政策、市场环境等不确定因素的影响，敬请广大投 资者谨慎决策，注意防范投资风险。 药品批准文号：国药准字 H20254671、国药准字 H20254672 审批结论：根 ...

Group 1 - The company's main credit rating remains "AA" with a stable outlook [1] - The tracking credit rating for the "Huahai Convertible Bond" is also maintained at "AA" [1] - The rating was conducted by Shanghai New Century Credit Rating Investment Service Co., Ltd. based on a comprehensive analysis of the company's industry and operational status [1] Group 2 - The previous credit rating results for the company and the convertible bond were both "AA" as of June 28, 2024 [1] - The announcement is made in accordance with the relevant regulations of the Securities Issuance Registration Management Measures and the Shanghai Stock Exchange Listing Rules [1] - The announcement was issued by the Board of Directors of Zhejiang Huahai Pharmaceutical Co., Ltd. on June 27, 2025 [2]

| | | 根据《上市公司证券发行注册管理办法》和《上海证券交易所股票上市规则》等 有关规定，浙江华海药业股份有限公司（以下简称"公司"）委托信用评级机构上海 新世纪资信评估投资服务有限公司（以下简称"新世纪评估"）对公司于 2020 年 11 月 2 日公开发行的可转换公司债券（转债简称"华海转债"）进行了跟踪评级。 公司前次主体信用评级结果为"AA"，"华海转债"前次评级结果为"AA "， 评级机构为新世纪评估，评级时间为 2024 年 6 月 28 日。 新世纪评估在对公司所属行业及经营状况等进行综合分析与评估的基础上，于 2025 年 6 月 26 日出具了《2020 年浙江华海药业股份有限公司公开发行可转换公司债 券定期跟踪评级报告》【新世纪跟踪（2025）100187】，维持公司"AA"的主体信用等 级，评级展望维持"稳定"，同时维持"华海转债"跟踪信用等级"AA"。 特此公告。 浙江华海药业股份有限公司 董 事 会 股票简称：华海药业 股票代码：600521 公告编号：临 2025-076 号 浙江华海药业股份有限公司 关于"华海转债"2025 年跟踪评级结果的公告 本公司董事会及全体董事保证本 ...

内部编号:2025060255 2020 年浙江华海药业股份有限公司 公开发行可转换公司债券 定期跟踪评级报告 项目负责人: 王婷亚 翁斯詰 子的女 wty@shxsj.com ch = $11 1 6-5 wsz@shxsj.com 项目组成员: 张明海 Press 16.1 评级总监: 联系电话:(021)63501349 联系地址:上海市黄浦区汉口路 398 号华盛大厦 14 层 公司网站：www.shxsj.com 上海新世纪资信评估投资服务有限公司 Shanghai Brilliance Credit Rating & Investors Service Co., Ltd. 11 | | 跟踪评级概要 | | --- | --- | | 编号:【新世纪跟踪(2025)100187】 | | | 评级对象: | 2020年浙江华海药业股份有限公司公 | | | 华海转债 | | | 主体/展望/债项/评级时间 | | 本次跟踪: | AA/稳定/AA/2025年6月26日 | | 前次跟踪: | AA/稳定/AA/2024 年 6 月 28 日 | | 首次评级: | AA/稳定/AA/2020年6月 ...

Market Performance - The cell immunotherapy sector declined by 1.41%, ranking among the top losers in the concept sector as of the market close on June 26 [1] - Notable declines were observed in companies such as Rongchang Biologics, Yuyuan Pharmaceutical, and Huahai Pharmaceutical, while ST Xiangxue, Shutai Shen, and Tailin Biologics saw gains of 4.19%, 1.71%, and 1.42% respectively [1] Capital Flow - The cell immunotherapy sector experienced a net outflow of 796 million yuan, with 43 stocks facing net outflows, and 5 stocks seeing outflows exceeding 50 million yuan [1] - Rongchang Biologics led the outflow with 110 million yuan, followed by Hengrui Medicine, Huahai Pharmaceutical, and Yuyuan Pharmaceutical with outflows of 104 million yuan, 75 million yuan, and 70 million yuan respectively [1] Top Gainers and Losers - The top gainers in the cell immunotherapy sector included ST Xiangxue, Shutai Shen, and Tailin Biologics, while the largest losers were Rongchang Biologics, Hengrui Medicine, and Huahai Pharmaceutical [1][3] - The trading volume for Rongchang Biologics was notably high, with a turnover rate of 14.96% and a significant drop of 18.36% in stock price [2][3]

Group 1 - The company announced a cash dividend of 0.25 yuan per share (including tax) to all shareholders based on the total share capital after deducting shares held in the repurchase account [1][3] - The company will stop the conversion of its convertible bonds ("华海转债") from July 1, 2025, until the record date for the dividend distribution, with resumption of conversion on the first trading day after the record date [1][3] - The company will adjust the conversion price of the convertible bonds according to the terms outlined in the bond issuance prospectus after the implementation of the profit distribution plan [3] Group 2 - The company held its annual general meeting on May 23, 2025, where the profit distribution plan was approved [1][2] - The company will publish the implementation announcement of the profit distribution and the adjustment of the convertible bond conversion price on July 2, 2025 [3] - Shareholders wishing to enjoy the dividend distribution must convert their bonds by June 30, 2025 [3]

证券代码：600521 证券简称：华海药业 公告编号：临 2025-075 号 转债代码：110076 转债简称：华海转债 浙江华海药业股份有限公司 一、2024 年度权益分派方案的基本情况 浙江华海药业股份有限公司（以下简称"公司"）于 2025 年 5 月 23 日召开 2024 年年度股东大会，会议审议通过了《公司 2024 年度利润分配方案》，公司以实施 权益分派股权登记日登记的总股本扣除公司回购专用证券账户股份数后的股本为 基数，向全体股东每股派发现金红利 0.25 元（含税）。公司通过回购专用证券账 户所持有本公司股份不参与本次利润分配。如在实施权益分派股权登记日期前， 因可转债转股、回购股份注销等致使公司总股本发生变动的，公司将维持每股分 配金额不变，相应调整分配总额。 具体内容详见公司分别于 2025 年 4 月 30 日、2025 年 5 月 24 日刊登在中国证 券报、上海证券报、证券时报、证券日报及上海证券交易所网站（www.sse.com.cn） 关于实施 2024 年度权益分派时"华海转债"停止转股 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或 ...

Group 1 - The core viewpoint of the report is the management of the convertible bonds issued by Zhejiang Huahai Pharmaceutical Co., Ltd., including the bond's issuance details, credit ratings, and the use of raised funds [1][2][3][4][5][6][7][8][9] Group 2 - The total amount of the convertible bonds issued is 1,842.60 million yuan, with a term of 6 years and an interest rate that varies from 0.30% in the first year to 1.00% in the third year [1][2] - The funds raised will be allocated to various projects, including 692.60 million yuan for the production of 20 tons of Perindopril and 50 tons of Ramipril, and 600 million yuan for a pharmaceutical and R&D center project [1][6] - The company has maintained a credit rating of AA for both the issuer and the bonds, with a stable outlook [1][2][3] Group 3 - The company reported a 14.91% increase in total revenue for 2024, amounting to 954,742.54 million yuan compared to 830,871.98 million yuan in 2023 [5] - The net profit for 2024 reached 110,746.31 million yuan, reflecting a 35.51% increase from the previous year [5] - The company’s total assets and liabilities remained stable, with total liabilities at 112.41 billion yuan as of December 31, 2024 [7][9] Group 4 - The company has established a mechanism for the management of raised funds, ensuring compliance with the intended use as outlined in the bond issuance documents [6][7] - The company has successfully completed the projects funded by the raised capital, including the production of raw materials and the establishment of a pharmaceutical park [6][7] - The company has reported no significant adverse changes in its operating environment or business continuity [4][6]

浙商证券股份有限公司 关于 浙江华海药业股份有限公司 公开发行可转换公司债券 受托管理事务报告 （2024 年度） | 债券代码 | 债券简称 | | --- | --- | | 110076 | 华海转债 | 债券受托管理人 （注册地址：浙江省杭州市五星路 201 号） 二〇二五年六月 1 | 重要声明 2 | | --- | | 目录 3 | | 第一章 本次债券情况 4 | | 第二章 受托管理人履行职责情况 6 | | 第三章 发行人的经营与财务状况 8 | | 第四章 发行人募集资金使用及专项账户运作情况与核查情况 11 | | 第五章 内外部增信机制、偿债保障措施的有效性分析 17 | | 第六章 债券本息偿付情况以及发行人偿债保障措施的执行情况 18 | | 第七章 发行人在募集说明书中约定的其他义务的执行情况 19 | | 第八章 债券持有人会议的召开情况 20 | | 第九章 发行人偿债意愿和能力分析 21 | | 第十章 可能影响发行人偿债能力的重大事项及受托管理人采取的应对措施 23 | | 第十一章 其他事项 24 | 第一章 本次债券情况 一、可转换公司债券基本情况 重要声明 浙商证 ...